Metabolic FingerPrinting (MetaPrint)

Arcensus

Status: Enrolling

Conditions: Genetic Disease

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT05305729

MetaPrint-2021

Details and patient eligibility

About

The MetaPrint study aims to characterize the metabolic fingerprint of genetic diseases in order to enhance knowledge on the physiological disease status and establish so new tools for diagnosing, monitoring and personalizing treatment of genetic diseases.

Enrollment: 10,000 estimated patients

Sex: All

Ages: 2+ months old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent is obtained from the participant or from the parent/ legal guardian
• The participant is 2 months or older
• The participant is diagnosed with a genetic disease
• The participant is a first degree relative of a subject diagnosed with a genetic disease

Exclusion criteria

• Informed consent is not obtained from the participant or from the parent/ legal guardian
• The participant is younger than 2 months
• The participant is not diagnosed with a genetic disease
• The participant is not a first degree relative of a subject diagnosed with a genetic disease

Trial design

10,000 participants in 1 patient group

Subjects with a genetic disease

Treatment:

Other: No intervention